Abstract
Transcatheter aortic valve implantation (TAVI) is an established treatment option for patients with severe aortic stenosis. Patients with aortic stenosis have a higher prevalence of chronic kidney disease (CKD). CKD is generally associated with an increased risk of mortality, cardiovascular events, and readmission for heart failure; this supports the concept of a cardio-renal syndrome (CRS). CRS encompasses a spectrum of disorders of the heart and kidneys, wherein dysfunction in one organ may cause dysfunction in the other. TAVI treatment is expected to break this malignant cycle of CRS and improve cardio-renal function after the procedure. However, several reports demonstrate that patients with CKD have been associated with poor outcomes after the procedure. In addition, TAVI treatments for patients with advanced CKD and those with end-stage renal disease on hemodialysis are considered more challenging. Adequate management to preserve cardio-renal function in patients undergoing TAVI may reduce the risk of cardio-renal adverse events and improve the long-term prognosis. The current comprehensive review article aims to assess the prognostic impact of CKD after TAVI and seek optimal care in patients with CKD even after successful TAVI.
Similar content being viewed by others
References
Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–15607. https://doi.org/10.1056/NEJMoa1008232.
Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98. https://doi.org/10.1056/NEJMoa1103510.
Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20. https://doi.org/10.1056/NEJMoa1514616.
Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–705. https://doi.org/10.1056/NEJMoa1814052.
Yamamoto M, Hayashida K, Mouillet G, Hovasse T, Chevalier B, Oguri A, et al. Prognostic value of chronic kidney disease after transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;62:869–77. https://doi.org/10.1016/j.jacc.2013.04.057.
Oguri A, Yamamoto M, Mouillet G, Gilard M, Laskar M, Eltchaninoff H, et al. Impact of chronic kidney disease on the outcomes of transcatheter aortic valve implantation: results from the FRANCE 2 registry. EuroIntervention. 2015;10:e1–9. https://doi.org/10.4244/EIJV10I9A183.
Codner P, Levi A, Gargiulo G, Praz F, Hayashida K, Watanabe Y, et al. Impact of renal dysfunction on results of transcatheter aortic valve replacement outcomes in a large multicenter cohort. Am J Cardiol. 2016;118:1888–96. https://doi.org/10.1016/j.amjcard.2016.08.082.
Gracia E, Wang TY, Callahan S, Bilfinger T, Tannous H, Pyo R, et al. Impact of severity of chronic kidney disease on management and outcomes following transcatheter aortic valve replacement with newer-generation transcatheter valves. J Invas Cardiol. 2020;32:25–9.
Franzone A, Stortecky S, Pilgrim T, Asami M, Lanz J, Heg D, et al. Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. Int J Cardiol. 2018;250:73–9. https://doi.org/10.1016/j.ijcard.2017.09.201.
Gupta T, Goel K, Kolte D, Khera S, Villablanca PA, Aronow WS, et al. Association of chronic kidney disease with in-hospital outcomes of transcatheter aortic valve replacement. JACC Cardiovasc Intv. 2017;10:2050–60. https://doi.org/10.1016/j.jcin.2017.07.044.
Adachi Y, Yamamoto M, Shimura T, Yamaguchi R, Kagase A, Tokuda T, et al. Late kidney injury after transcatheter aortic valve replacement. Am Heart J. 2021;234:122–30. https://doi.org/10.1016/j.ahj.2021.01.007.
Beohar N, Doshi D, Thourani V, Jensen H, Kodali S, Zhang F, et al. Association of transcatheter aortic valve replacement with 30-day renal function and 1-year outcomes among patients presenting with compromised baseline renal function: experience from the PARTNER 1 trial and registry. JAMA Cardiol. 2017;2:742–9. https://doi.org/10.1001/jamacardio.2017.1220.
Witberg G, Steinmetz T, Landes U, Pistiner Hanit R, Green H, Goldman S, et al. Change in kidney function and 2-year mortality after transcatheter aortic valve replacement. JAMA Netw Open. 2021;4: e213296. https://doi.org/10.1001/jamanetworkopen.2021.3296.
Cubeddu RJ, Asher CR, Lowry AM, Blackstone EH, Kapadia SR, Alu MC, et al. Impact of transcatheter aortic valve replacement on severity of chronic kidney disease. J Am Coll Cardiol. 2020;76:1410–21. https://doi.org/10.1016/j.jacc.2020.07.048.
Liao YB, Deng XX, Meng Y, Zhao ZG, Xiong TY, Meng XJ, et al. Predictors and outcome of acute kidney injury after transcatheter aortic valve implantation: a systematic review and meta-analysis. EuroIntervention. 2017;12:2067–74. https://doi.org/10.4244/EIJ-D-15-00254.
Najjar M, Salna M, George I. Acute kidney injury after aortic valve replacement: incidence, risk factors and outcomes. Expert Rev Cardiovasc Ther. 2015;13:301–16. https://doi.org/10.1586/14779072.2015.1002467.
Yamamoto M, Hayashida K, Mouillet G, Chevalier B, Meguro K, Watanabe Y, et al. Renal function-based contrast dosing predicts acute kidney injury following transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2013;6:479–86. https://doi.org/10.1016/j.jcin.2013.02.007.
Thongprayoon C, Cheungpasitporn W, Gillaspie EA, Greason KL, Kashani KB. The risk of acute kidney injury following transapical versus transfemoral transcatheter aortic valve replacement: a systematic review and meta-analysis. Clin Kidney J. 2016;9:560–6. https://doi.org/10.1093/ckj/sfw055.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1–266.
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31:703–11. https://doi.org/10.1093/eurheartj/ehp507.
Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation. 2019;139:e840–78. https://doi.org/10.1161/CIR.0000000000000664.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39. https://doi.org/10.1016/j.jacc.2008.07.051.
Vavilis G, Bäck M, Occhino G, Trevisan M, Bellocco R, Evans M, et al. Kidney dysfunction and the risk of developing aortic stenosis. Am J Cardiol. 2022;163:58–64.
D’Ascenzo F, Moretti C, Salizzoni S, Bollati M, D’Amico M, Ballocca F, et al. 30 days and midterm outcomes of patients undergoing percutaneous replacement of aortic valve according to their renal function: a multicenter study. Int J Cardiol. 2013;167:1514–8. https://doi.org/10.1016/j.ijcard.2012.04.161.
Dumonteil N, van der Boon RM, Tchetche D, Chieffo A, Van Mieghem NM, Marcheix B, et al. Impact of preoperative chronic kidney disease on short- and long-term outcomes after transcatheter aortic valve implantation: a Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. Am Heart J. 2013;165:752–60. https://doi.org/10.1016/j.ahj.2012.12.013.
Nguyen TC, Babaliaros VC, Razavi SA, Kilgo PD, Guyton RA, Devireddy CM, et al. Impact of varying degrees of renal dysfunction on transcatheter and surgical aortic valve replacement. J Thorac Cardiovasc Surg. 2013;146:1399–13406. https://doi.org/10.1016/j.jtcvs.2013.07.065 (discussion 13406–7).
Ferro CJ, Chue CD, de Belder MA, Moat N, Wendler O, Trivedi U, et al. Impact of renal function on survival after transcatheter aortic valve implantation (TAVI): an analysis of the UK TAVI registry. Heart. 2015;101:546–52. https://doi.org/10.1136/heartjnl-2014-307041.
Nijenhuis VJ, Peper J, Vorselaars VMM, Swaans MJ, De Kroon T, Van der Heyden JAS, et al. Prognostic value of improved kidney function after transcatheter aortic valve implantation for aortic stenosis. Am J Cardiol. 2018;121:1239–45. https://doi.org/10.1016/j.amjcard.2018.01.049.
Azarbal A, Leadholm KL, Ashikaga T, Solomon RJ, Dauerman HL. Frequency and prognostic significance of acute kidney recovery in patients who underwent transcatheter aortic valve implantation. Am J Cardiol. 2018;121:634–41. https://doi.org/10.1016/j.amjcard.2017.11.043.
VARC-3 Writing Committee, Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42:1825–57. https://doi.org/10.1093/eurheartj/ehaa799.
Yamamoto M, Watanabe Y, Tada N, Naganuma T, Araki M, Yamanaka F, et al. Transcatheter aortic valve replacement outcomes in Japan: optimized CathEter valvular iNtervention (OCEAN) Japanese multicenter registry. Cardiovasc Revasc Med. 2019;20:843–51. https://doi.org/10.1016/j.carrev.2018.11.024.
Adachi Y, Yamamoto M, Shimura T, Yamaguchi R, Kagase A, Tokuda T, et al. Late adverse cardiorenal events of catheter procedure-related acute kidney injury after transcatheter aortic valve implantation. Am J Cardiol. 2020;133:89–97. https://doi.org/10.1016/j.amjcard.2020.07.041.
Julien HM, Stebbins A, Vemulapalli S, Nathan AS, Eneanya ND, Groeneveld P, et al. Incidence, predictors, and outcomes of acute kidney injury in patients undergoing transcatheter aortic valve replacement: insights from the Society of Thoracic Surgeons/American College of Cardiology national cardiovascular data registry-transcatheter valve therapy registry. Circ Cardiovasc Interv. 2021;14: e010032. https://doi.org/10.1161/CIRCINTERVENTIONS.120.010032.
Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. N Engl J Med. 2019;380:2146–55. https://doi.org/10.1056/NEJMra1805256.
Eskandari M, Aldalati O, Byrne J, Dworakowski R, Wendler O, Alcock E, et al. Zero contrast transfemoral transcatheter aortic valve replacement using fluoroscopy-echocardiography fusion imaging. Am J Cardiol. 2016;117:1861–2. https://doi.org/10.1016/j.amjcard.2016.03.028.
Maffeo D, Bettari L, Latib A, Maiandi C, Villa E, Messina A, et al. Transfemoral transcatheter aortic valve replacement without contrast medium using the Medtronic CoreValve system: a single center experience. J Cardiovasc Surg (Torino). 2020;61:489–95. https://doi.org/10.23736/S0021-9509.20.11083-8.
Blair JEA, Brummel K, Friedman JL, Atri P, Sweis RN, Russell H, et al. Inhospital and post-discharge changes in renal function after transcatheter aortic valve replacement. Am J Cardiol. 2016;117:633–69. https://doi.org/10.1016/j.amjcard.2015.11.047.
Jäckel M, Keller S, Prager EP, Staudacher DL, Schlett C, Zehender M, et al. The impact of transcatheter aortic valve implantation planning and procedure on acute and chronic renal failure. Cardiol J. 2021. https://doi.org/10.5603/CJ.a2021.0057.
Sabe MA, Claggett B, Burdmann EA, Desai AS, Ivanovich P, Kewalramani R, et al. Coronary artery disease is a predictor of progression to dialysis in patients with chronic kidney disease, type 2 diabetes mellitus, and anemia: an analysis of the trial to reduce cardiovascular events with Aranesp therapy (TREAT). J Am Heart Assoc. 2016;5: e002850. https://doi.org/10.1161/JAHA.115.002850.
Bansal N, Katz R, Robinson-Cohen C, Odden MC, Dalrymple L, Shlipak MG, et al. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies. JAMA Cardiol. 2017;2:314–8. https://doi.org/10.1001/jamacardio.2016.4652.
Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol. 2007;18:1307–15. https://doi.org/10.1681/ASN.2006101159.
Goel SS, Agarwal S, Tuzcu EM, Ellis SG, Svensson LG, Zaman T, et al. Percutaneous coronary intervention in patients with severe aortic stenosis: implications for transcatheter aortic valve replacement. Circulation. 2012;125:1005–13. https://doi.org/10.1161/CIRCULATIONAHA.111.039180.
Faroux L, Campelo-Parada F, Munoz-Garcia E, Nombela-Franco L, Fischer Q, Donaint P, et al. Procedural characteristics and late outcomes of percutaneous coronary intervention in the workup pre-TAVR. JACC Cardiovasc Interv. 2020;13:2601–13. https://doi.org/10.1016/j.jcin.2020.07.009.
Hioki H, Watanabe Y, Kozuma K, Nara Y, Kawashima H, Kataoka A, et al. Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding. Heart. 2017;103:361–437. https://doi.org/10.1136/heartjnl-2016-309735.
Li SX, Patel NK, Flannery LD, Cigarroa RJ, Shaqdan AW, Erickson P, et al. Impact of bleeding after transcatheter aortic valve replacement in patients with chronic kidney disease. Catheter Cardiovasc Interv. 2021;97:E172–8. https://doi.org/10.1002/ccd.28989.
Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. ACTIVATION (Percutaneous Coronary intervention prior to transcatheter aortic valve implantation): a randomized clinical trial. JACC Cardiovasc Intv. 2021;14:1965–74. https://doi.org/10.1016/j.jcin.2021.06.041.
Ochiai T, Yoon SH, Flint N, Sharma R, Chakravarty T, Kaewkes D, et al. Timing and outcomes of percutaneous coronary intervention in patients who underwent transcatheter aortic valve implantation. Am J Cardiol. 2020;125:1361–8. https://doi.org/10.1016/j.amjcard.2020.01.043.
Writing Committee Members, Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, et al. ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2021;77:450–500.
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632.
Stabile E, Pucciarelli A, Cota L, Sorropago G, Tesorio T, Salemme L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol. 2014;174:624–7. https://doi.org/10.1016/j.ijcard.2014.04.170.
Rodés-Cabau J, Masson JB, Welsh RC, Garcia Del Blanco B, Pelletier M, Webb JG, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357–65. https://doi.org/10.1016/j.jcin.2017.04.014.
Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;383:1447–57.
Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;382:1696–707.
Mentias A, Desai MY, Saad M, Horwitz PA, Rossen JD, Panaich S, et al. Management of aortic stenosis in patients with end-stage renal disease on hemodialysis. Circ Cardiovasc Interv. 2020;13: e009252. https://doi.org/10.1161/CIRCINTERVENTIONS.120.009252.
Ogami T, Kurlansky P, Takayama H, Ning Y, Zimmermann E, Zhu RC, et al. Three-year survival of transcatheter versus surgical aortic valve replacement in dialysis. Catheter Cardiovasc Interv. 2022. https://doi.org/10.1002/ccd.30045.
Szerlip M, Zajarias A, Vemalapalli S, Brennan M, Dai D, Maniar H, et al. Transcatheter aortic valve replacement in patients with end-stage renal disease. J Am Coll Cardiol. 2019;73:2806–15. https://doi.org/10.1016/j.jacc.2019.03.496.
Kuno T, Takagi H, Ando T, Ueyama H, Fujisaki T, Kodaira M, et al. Short- and long-term outcomes in dialysis patients undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis. Can J Cardiol. 2020;36:1754–63. https://doi.org/10.1016/j.cjca.2020.01.015.
Kawase Y, Taniguchi T, Morimoto T, Kadota K, Iwasaki K, Kuwayama A, et al. Severe aortic stenosis in dialysis patients. J Am Heart Assoc. 2017;6: e004961. https://doi.org/10.1161/JAHA.116.004961.
Funding
None.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
Dr. Yamamoto is a clinical proctor for Edwards Lifesciences and Medtronic. Dr. Adachi has nothing to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Adachi, Y., Yamamoto, M. & the OCEAN-SHD family. Chronic kidney disease and transcatheter aortic valve implantation. Cardiovasc Interv and Ther 37, 458–464 (2022). https://doi.org/10.1007/s12928-022-00859-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12928-022-00859-x